Omics-Mediated Treatment for Advanced Prostate Cancer: Moving Towards Precision Oncology.

ABSTRACT: Prostate cancer accounts for approximately 1.5 million new diagnoses and 400,000 deaths every year worldwide, and demographic projections indicate a near-doubling of both figures by 2040. Despite existing treatments, 10-20% of patients eventually progress to metastatic castration-resistant disease (mCRPC). The median overall survival (OS) after progression to mCPRC drops to 24 months, and efficacy drops severely after each additional line of treatment. Omics platforms have reached advanced levels and enable the acquisition of high-resolution large datasets that can provide insights into the molecular mechanisms underlying PCa pathology. Genomics, especially DDR (DNA damage response) gene alterations, detected via tissue and/or circulating tumor DNA, efficiently guides therapy in advanced p

SUBMITTER: Fatima Y 

PROVIDER: S-EPMC12347257 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature